Geoffrey R. Oxnard
Experienced in Metastatic Pleural Tumor

Dr. Geoffrey R. Oxnard

Oncology
Evans Medical Foundation Inc
88 E Newton St, Evans 124, 
Boston, MA 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Experienced in Metastatic Pleural Tumor
Evans Medical Foundation Inc
88 E Newton St, Evans 124, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Geoffrey Oxnard is an Oncologist in Boston, Massachusetts. Dr. Oxnard is rated as an Experienced provider by MediFind in the treatment of Metastatic Pleural Tumor. His top areas of expertise are EGFR Positive Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Lung Adenocarcinoma, and Tissue Biopsy. Dr. Oxnard is currently accepting new patients.

His clinical research consists of co-authoring 198 peer reviewed articles and participating in 23 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in MA
Hospital Affiliations
Boston Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

EVANS MEDICAL FOUNDATION INC
88 E Newton St, Evans 124, Boston, MA 02118
Other Locations
EVANS MEDICAL FOUNDATION INC
1 Boston Medical Ctr Pl, Boston, MA 02118

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

20 Clinical Trials

A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care
A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care
Enrollment Status: Recruiting
Publish Date: February 05, 2025
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Recruiting
Publish Date: July 03, 2024
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: October 06, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
ALCMI-011: Study of Plasma Next Generation Sequencing for Assessment, Characterization, Evaluation of Patients With ALK Resistance (SPACEWALK)
ALCMI-011: Study of Plasma Next Generation Sequencing for Assessment, Characterization, Evaluation of Patients With ALK Resistance (SPACEWALK)
Enrollment Status: Completed
Publish Date: October 02, 2025
A Multi-arm, Phase Ib, Open-Label, Multicentre Study to Assess the Safety,Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9291 in Combination With Ascending Doses of Novel Therapeutics in Patients With EGFRm+ Advanced NSCLC Who Have Progressed Following Therapy With an EGFR TKI (TATTON).
A Multi-arm, Phase Ib, Open-Label, Multicentre Study to Assess the Safety,Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9291 in Combination With Ascending Doses of Novel Therapeutics in Patients With EGFRm+ Advanced NSCLC Who Have Progressed Following Therapy With an EGFR TKI (TATTON).
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug
Study Drugs: AZD9291+AZD6094, AZD9291+Selumetinib, AZD9291+MEDI4736, AZD6094
Study Phase: Phase 1
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
A Phase II Study Assessing the Efficacy of Osimertinib in Combination With Savolitinib in Patients With EGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Progressed Following Treatment With Osimertinib.
A Phase II Study Assessing the Efficacy of Osimertinib in Combination With Savolitinib in Patients With EGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Progressed Following Treatment With Osimertinib.
Enrollment Status: Active_not_recruiting
Publish Date: May 08, 2025
Intervention Type: Drug
Study Drug: Osimertinib
Study Phase: Phase 2
LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Selpercatinib, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab
Study Phase: Phase 3
INHERIT EGFR - INvestigating HEreditary RIsk From T790M: A Multi-Centered Study to Identify and Characterize Individuals Carrying Germline EGFR Mutations
INHERIT EGFR - INvestigating HEreditary RIsk From T790M: A Multi-Centered Study to Identify and Characterize Individuals Carrying Germline EGFR Mutations
Enrollment Status: Active_not_recruiting
Publish Date: April 17, 2025
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Enrollment Status: Approved_for_marketing
Publish Date: January 17, 2025
Intervention Type: Drug
Afatinib Sequenced With Concurrent Chemotherapy and Radiation in EGFR-Mutant Non-Small Cell Lung Tumors: The ASCENT Trial
Afatinib Sequenced With Concurrent Chemotherapy and Radiation in EGFR-Mutant Non-Small Cell Lung Tumors: The ASCENT Trial
Enrollment Status: Active_not_recruiting
Publish Date: November 20, 2024
Intervention Type: Procedure, Drug, Radiation
Study Drugs: Afatinib, Cisplatin, Pemetrexed
Study Phase: Phase 2
A Phase 1B Study of AZD9291 in Combination With Navitoclax in EGFR-Mutant Non-Small Cell Lung Cancer Following Resistance to Initial EGFR Kinase Inhibitor
A Phase 1B Study of AZD9291 in Combination With Navitoclax in EGFR-Mutant Non-Small Cell Lung Cancer Following Resistance to Initial EGFR Kinase Inhibitor
Enrollment Status: Completed
Publish Date: August 21, 2024
Intervention Type: Drug
Study Drugs: Navitoclax, Osimertinib
Study Phase: Phase 1
The Circulating Cell-free Genome Atlas Study
The Circulating Cell-free Genome Atlas Study
Enrollment Status: Unknown
Publish Date: September 13, 2023
The PATHFINDER Study: Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test Into Clinical Practice
The PATHFINDER Study: Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test Into Clinical Practice
Enrollment Status: Completed
Publish Date: October 25, 2022
Intervention Type: Device
Study Phase: Not Applicable
Genomics of Young Lung Cancer Study
Genomics of Young Lung Cancer Study
Enrollment Status: Completed
Publish Date: November 18, 2021
Intervention Type: Other
Phase 1/2, First-in-Human, Dose-Escalation Study of X-396 (Ensartinib) in Patients With Advanced Solid Tumors and Expansion Phase in Patients With ALK-positive Non-Small Cell Lung Cancer
Phase 1/2, First-in-Human, Dose-Escalation Study of X-396 (Ensartinib) in Patients With Advanced Solid Tumors and Expansion Phase in Patients With ALK-positive Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: October 06, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer
Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer
Enrollment Status: Terminated
Publish Date: November 22, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Terminated
Publish Date: August 05, 2019
Intervention Type: Drug, Radiation
Study Phase: Phase 2
A Phase II Trial of Sunitinib in Never-smokers With Lung Adenocarcinoma: Identification of Oncogenic Alterations Underlying Sunitinib Sensitivity
A Phase II Trial of Sunitinib in Never-smokers With Lung Adenocarcinoma: Identification of Oncogenic Alterations Underlying Sunitinib Sensitivity
Enrollment Status: Completed
Publish Date: October 31, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 18 Less Clinical Trials

198 Total Publications

Benefits of Combining Circulating Tumor DNA With Tissue and Longitudinal Circulating Tumor DNA Genotyping in Advanced Solid Tumors: SCRUM-Japan MONSTAR-SCREEN-1 Study.
Benefits of Combining Circulating Tumor DNA With Tissue and Longitudinal Circulating Tumor DNA Genotyping in Advanced Solid Tumors: SCRUM-Japan MONSTAR-SCREEN-1 Study.
Journal: JCO precision oncology
Published: April 10, 2025
Similar Doctors
Distinguished in Metastatic Pleural Tumor
Dr. David J. Kwiatkowski
Oncology
Distinguished in Metastatic Pleural Tumor
Dr. David J. Kwiatkowski
Oncology

Dana-Farber Cancer Institute, Inc.

450 Brookline Ave, 
Boston, MA 
 (1.9 miles away)
Experience:
46+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Kwiatkowski is an Oncologist in Boston, Massachusetts. Dr. Kwiatkowski has been practicing medicine for over 46 years and is rated as an Elite provider by MediFind in the treatment of Metastatic Pleural Tumor. His top areas of expertise are Lung Adenocarcinoma, Lung Cancer, Mesothelioma, and Non-Small Cell Lung Cancer (NSCLC).

Distinguished in Metastatic Pleural Tumor
Dr. Michael S. Rabin
Oncology | Hematology
Distinguished in Metastatic Pleural Tumor
Dr. Michael S. Rabin
Oncology | Hematology

Dana-Farber Cancer Institute, Inc.

450 Brookline Ave, 
Boston, MA 
 (1.9 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Rabin is an Oncologist and a Hematologist in Boston, Massachusetts. Dr. Rabin is rated as an Elite provider by MediFind in the treatment of Metastatic Pleural Tumor. His top areas of expertise are EGFR Positive Lung Cancer, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Lung Adenocarcinoma. Dr. Rabin is currently accepting new patients.

Distinguished in Metastatic Pleural Tumor
Dr. David M. Jackman
Oncology
Distinguished in Metastatic Pleural Tumor
Dr. David M. Jackman
Oncology

Dana-Farber Cancer Institute, Inc.

300 Boylston St, Suite 301, 
Chestnut Hill, MA 
 (5.7 miles away)
617-632-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Jackman is an Oncologist in Chestnut Hill, Massachusetts. Dr. Jackman is rated as an Elite provider by MediFind in the treatment of Metastatic Pleural Tumor. His top areas of expertise are EGFR Positive Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, and Mesothelioma. Dr. Jackman is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Oxnard's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
    View All 18 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile